API | farglitazar

farglitazar Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy. After reaching phase III for type 2 diabetes, further development was discontinued. ^Wikipedia

Chemistry

SMILES: Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1
InChIKey: ZZCHHVUQYRMYLW-HKBQPEDESA-N
Mol. Mass: 546.62
ALogP: 6.61 Partition coefficient
ChEMBL Molecule:
farglitazar

More Chemistry

Pharmacology

Mechanism of Action:
- Peroxisome proliferator-activated receptor gamma (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

farglitazar | gi2570 | gi 2570 | gi-2570 | gi262570 | gi 262570 | gi-262570 | gi-262570x

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Liver Cirrhosis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue